GlassScriptPhysician profile
Amanda Stewart
NPI 1548756778
$1,265.31
in general payments reported to CMS, 2019-2025
14 companies · $58.09 in 2025
The $58.09 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $200 · 2022: $388 · 2023: $384 · 2024: $235 · 2025: $58.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $227.08 | 2023-2024 | Dupixent |
| Lilly USA, LLC | $219.64 | 2021-2023 | Mounjaro, Trulicity, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.02 | 2021-2025 | Jardiance, Tradjenta |
| Abbvie INC. | $156.56 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2023 | |
| Corium, LLC | $125.00 | 2022 | |
| Itamar Medical INC | $57.45 | 2023 | Watchpatone |
| Astellas Pharma US INC | $34.66 | 2024 | Veozah |
| Amgen INC. | $32.40 | 2024 | Otezla, Repatha |
| Genentech USA, INC. | $28.15 | 2021-2023 | |
| Evoke Pharma, INC. | $20.21 | 2021 | |
| Axsome Therapeutics, INC. | $14.45 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $13.91 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.